
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - Etanercept (Enbrel) produces rapid, significant, and sustained improvement in symptoms in patients with moderate to severe psoriasis, according to the results of a large, multicenter Phase III study presented by Alice Gottlieb, MD, Ph.D.






